ARKK
ARK’s latest exit hatch
Cathie Wood’s ARK Invest is still doing spring cleaning in Strata Critical Medical. On April 13, the firm sold 182,767 shares across two ARK ETFs, worth about $738,378.
Not exactly a one-day fling
This wasn’t a random trim either. The latest sale follows more than 75,000 shares sold on April 10, so ARK has been steadily backing away from the name over several sessions.
Meanwhile, the bulls are still banging the table
Here’s the awkward part: two analysts recently kicked off coverage with Buy ratings and $8 price targets, while the consensus target sits around $9.08. With the stock near $4.12, that implies more than 120% upside on paper.
So you’ve got one camp saying “this could double,” and ARK saying “we’re good, thanks.” That kind of split usually makes investors ask whether the market is missing something — or whether the stock is just the kind of tiny, volatile name that can make everyone look either brilliant or ridiculous in a hurry.
Big picture: when a high-profile fund keeps selling into bullish analyst chatter, you probably want to know which story the market eventually believes.